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A B S T R A C T
We report clinically rare and serious adverse reactions that occurred after the co-administration of ranitidine,
ibuprofen and ciprofloxacin: completely reversible aseptic meningitis and irreversible bilateral sensorineural hearing
loss, tinnitus, and vestibulopathy. Recurrent urinary inflammations treated with antibacterials, classic familial mi-
graine, and allergy to trimethoprim-sulfamethoxazole and chromium were favourable predisposing factors for the ad-
verse event in this patient. A close chronological relation between administration of drugs (especially ibuprofen) and ad-
verse reactions was noted. No evidence of infection and/or autoimmune disease was found. The mechanism of these
serious events may be explained as a hypersensitive reaction affecting the meninges and, partially, cochlea.
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Introduction
Aseptic meningitis (AM), with or without other drug-
-induced neurological disorders, has been the subject of
several reviews1–4. We report a case of drug-induced AM
with ototoxic disturbances following the simultaneous
use of a nonsteroidal anti-inflammatory drug (NSAID)
ibuprofen, a histamine blocker ranitidine, and a fluori-
nated quinolone antibiotic ciprofloxacin (CPFX).
Case Report
The represented study followed principles in the Dec-
laration of Helsinki5. A 48-year-old-woman¸ mother of
two children, body mass 21.5 kg/m2, was suffering from
frequent tonsillitis, classic familial migraine and urinary
tract infections, and was allergic to chromium (occupa-
tional dermatitis) and trimethoprim-sulfamethoxazole
(dermatitis medicamentosa).
She was hospitalized due to a 5-day lasting fever (to
38°C) and dysuria, which were treated per os with amoxi-
cillin-clavulanate (Pliva, Zagreb, Croatia) and paraceta-
mol (Lek, Ljubljana, Slovenia) (1875 and 1000 mg/daily,
respectively). At admission, she was febrile, conscious
and cooperative. Physical and neurological examinations
were without other particularities. Blood pressure was
155/80 mm Hg, and heart rate 100 beats/min.
Laboratory tests disclosed neutrophilic leukocytosis
(leukocytes 13.2x103/mL, segmented neutrophils 85%)
without eosinophils, erythrocyte sedimentation rate of
50 mm/h, raised C-reactive protein (32 mg/L), IgG 18.7
g/L, fibrinogen 4.3 g/L, plasminogen activator inhibitor-1
4.36 mL, angiotensin-converting enzyme 65 mg (ref. va-
lue: 8–52), anti-streptolysin O titre (ASO) 1:166 Todd u,
and decreased level of C3 complement component (0.8
g/L). Free thyroxin (FT4-RIA) was raised to 105.9 nmol
(ref. value: 58–61). Human leukocyte antigens were -A2,
-A24, -B17, -B35, -DR3, – DR11, – DQ2, – DQ3. Other
components of the hemogram, routine chemistry, and
tests for enzymes, proteins and lipoproteins, coagulation,
hemostasis, autoimmune diseases and disorders of the
immune system (Antinuclear Antibody, Anti-DNA Anti-
body test) were normal. Serology against Brucella meli-
tensis, Chlamydia psittaci, Borrelia burgdorferi, Trepo-
nema pallidum and Toxoplasma gondii was negative.
Routine urinalysis showed lightly turbid, alkaline (>pH
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7) urine that was positive for nitrate, protein and bacte-
ria, and negative for glucose and ketones. Microscopic ex-
amination of sediment showed 35 leukocytes, many epi-
thelial cells and bacteria. Bacterial cultures from blood
and urine were sterile. Chest radiography, abdominal ul-
trasound, ophthalmological and gynaecological examina-
tions were normal.
The first two days, she received ibuprofen (Belupo,
Koprivnica, Croatia) (2x400 mg) and ranitidine (Pliva,
Zagreb, Croatia) (1x300 mg) orally. On the third day,
CPFX (Pliva, Zagreb, Croatia) (2x500 mg orally) was pre-
scribed due to presumed . At nightfall, the patient com-
plained of diffuse and painful »burning« dysesthesia of
the whole body, followed by headache, photophobia, neck
stiffness, nausea and drowsiness. On the 4th day, EEG
was moderately dysrhythmic. Routine and special skull
radiography, and computed tomography of the head were
unremarkable. Magnetic resonance imaging of the brain,
with and without gadolinium, showed hyperintensity on
T2-weighted images in both labyrinths, markedly on the
left. Cerebrospinal fluid (CSF) analysis showed lympho-
cytary pleocytosis, and dysfunction of the blood-brain
barrier (BBB) with definite intrathecal IgG synthesis
(Table 1). Ibuprofen and ranitidine were discontinued.
The day after, the meningeal syndrome completely re-
gressed. However, the patient was atactic. She com-
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TABLE 1
CEREBROSPINAL FLUID ANALYSIS OF PATIENT
Characteristics 1.st CSF
2.th CSF
(six months after)
Appearance Like water Like water
Total protein (mg/dl) 125 31
Total cell count (WBC/ìl) 118 3
Lymphocytes (%) 62 Nd
Activated lymphocytes (%) 6 Nd
Plasma cells (%) 1 Nd
Plasmacytoides lymphocytes (%) 3 Nd
Neutrophils, segmented (%) 4 Nd
Monocytes (%) 16 Nd
Activated monocytes (%) 6 Nd
Macrophages (%) 2 Nd
Glucose (mg/dl) 57 52
Concomitant serum glucose 107 91
Lactate (mmol/L) 2.51 1.8
Immunoglobulin G (g/L) 0.222 0.025
Immunoglobulin G quotient 13.3 3.0
Albumin (g/L) 0.62 0.18
Albumin, serum (g/L) 51.3 Nd
Albumin quotient 12.1 4.4
Intrathecal Immunoglobulin G synthetic rate 1.1 Nd
Blood CSF barrier function 74 143
Oligoclonal banding negative negative
CSF bacterial cultures* negative negative
Antibodies to major DNA and RNA viruses** negative negative
Antibodies to Borrelia burgdorferi negative negative
VDRL negative negative
Cryptococcal antigen test negative negative
*the presence of Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae, B- and D-group Streptococci, Listeria
monocytogenes, Mycobacterium was excluded.
**DNA viruses: HSV1, HSV2, VZV, CMV, EBV, HHV-6, PARVO B19; RNA viruses: PARAINFL. 1-3, PAROTITIS, MORBILLI, INFLU-
ENZA A and B, RUBELLA, RSV, HIV
Immunocomplexes were not investigated
plained of bilateral deafness with tinnitus. An audiogram
showed bilateral sensorineural hearing loss (SNHL),
with threshold of hearing around 25–35–30 dB (right),
and 50–55–50 dB (left). Acoustic reflex was positive. On
the left, we identified tinnitus (frequency 8000 Hz, inten-
sity 55 dB), absence of vestibular reflex, and abnormal
brainstem auditory-evoked potentials. Horizontal nys-
tagmus appeared by looking to the left. Visual and soma-
tosensory-evoked potentials were normal. Cutaneous im-
munofluorescence biopsy showed normal findings. CPFX
administration was stopped.
The patient was discharged after 10 days. Neurologi-
cal examination showed bilateral SNHL with tinnitus.
She received orally betahistine (Pliva, Zagreb, Croatia)
(2x12 mg/day).
Six months later, she was examined in a day hospital
because of arthromyalgias, headache, vertigo, bilateral
deafness and squeaky tinnitus on the left. Laboratory
tests were normal, except ASO, which continued to be
1:166 Todd u. A second lumbar tap showed CSF without
meningeal inflammatory signs (Table 1). An audiogram
verified SNHL with hearing threshold among 35–40–40
dB (right), and 40–45–45 dB (left). On the left, tinnitus
(frequency 4000 Hz, intensity 50 dB) and vestibulopathy
were confirmed.
The patient received intramuscularly diclofenac (Pli-
va, Zagreb, Croatia), (1x75 mg/day during 5 days), and
did not develop adverse reactions.
Discussion
The clinical picture, as described, is based on a close
chronology of administration/discontinuation of drugs,
and development/partial restitutio ad integrum of disor-
ders.
The drugs administered, in the recommended thera-
peutic range, were paracetamol, amoxycillin-clavulanate,
ranitidine, ibuprofen and CPFX. Although amoxycillin-
-clavulanate is rarely responsible for AM6, the first two
drugs did not case adverse effects. AM and rapid onset of
deafness developed only after the simultaneous adminis-
tration of the last three drugs. Ranitidine very rarely
causes AM7, and does not significantly alter the bioavai-
lability of CPFX8. Ibuprofen is the most common cause of
AM in monotherapy (32 published reports). Ibuprofen-
-induced AM is often recurrent and frequent in patients
with collagen (vascular) diseases3. Davison et al. report a
case with bilateral SNHL and tinnitus in ibuprofen-in-
duced AM, where ibuprofen was taken every six hours
for three months. The disturbances disappeared after
drug cessation9. Asperilla and Smego report a case of eosi-
nophilic meningitis associated with orally taken CPFX10.
Interactions between ranitidine/ibuprofen and raniti-
dine/CPFX are weak and of limited clinical significance11.
Although there is extensive documentation of the in vivo
and in vitro interactions between quinolones and NSAIDs,
minimal documentation of patients in whom a correla-
tion between central nervous system toxicity and con-
comitant administration of the two classes of drugs is
available. Moreover, this type of potentially very serious
interaction is not mentioned in the package inserts of the
marketed quinolones12. CPFX was shown to interact
with ibuprofen in vitro and in vivo, but less than with
other NSAIDs13. Ibuprofen prolongs CPFX half-life in
the serum, enhances its extravasal diffusion into tissues,
modifies its renal excretion, and allows its passage thro-
ugh the BBB, thus potentiating its neurotoxicity14. As an
inhibitor of CYP-mediated metabolism, CPFX may be re-
sponsible for the toxicity of co-administered ibuprofen by
decreasing its clearance8.
Correct identification of the causative drug responsi-
ble for AM and SHNL in our patient is uncertain. The in-
criminated drug(s) could be ibuprofen and/or ranitidine,
as the patient had never taken them before, and the AM
completely regressed after their cessation. Absence of
suggestive biological findings (pointing to infectious eti-
ology or rheumatological/connectivitis disturbances) sug-
gests an allergic/idiosyncratic reaction, which is presum-
ably a hypersensitivity reaction type III to ibuprofen
with a secondary, local inflammation process (vasculitis)
restricted in the meningae3. Increased serum concentra-
tion of FT4-RIA might also suggest a pharmacologi-
cally-induced barrier dysfunction15. We assume that bi-
lateral partial deafness was caused by a simultaneous
inflammatory dysfunction of cochlear vessels endothe-
lium. Gender, age, migraine, recurrent urinary inflam-
mations, and particularly allergy to trimethoprim-sul-
famethoxazole, might all contribute as predisposing
factors for the adverse reactions in this patient.
CPFX is probably not an offending agent for SNHL
and vestibulopathy, as the drug in vitro is harmless to the
sensory organs for hearing and equilibrium in the inner
ear16. Subsequent administration of diclofenac did not
cause any adverse reactions. Thus, the neurotoxic ad-
verse reactions of ibuprofen do not contraindicate the
use of other NSAIDs.
With this case report, we wanted to draw attention on
the possibility of AM onset as a severe consequence in
therapy with ibuprofen – alone or in combination with
other drugs. Re-administration of this drug to the pa-
tient would be a method of choice for confirmation of the
diagnosis. However, this was not done as we considered
this procedure as non-acceptable ethically.
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ASEPTI^KI MENINGITIS, PERCEPTIVNA GLUHO]A I VESTIBULOPATIJA IZAZVANI
LIJEKOVIMA. PRIKAZ BOLESNIKA
S A @ E T A K
Prikazuju se klini~ki rijetke i ozbiljne nuspojave izazvane primjenom ranitidina, ibuprofena i ciprofloksacina: potpu-
no povratni asepti~ki meningitis i nepovratna obostrana perceptivna gluho}a, tinitus i vestibulopatija. Opetovane upale
mokra}nih putova lije~ene antibioticima, klasi~na familijarna migrena te alergija na trimetoprim-sulfametoksazol i
kromove boje bile su predispozicijski ~imbenici za nastup tih nuspojava u bolesnice. Uska kronolo{ka spona bila je
opa`ena izme|u primjene lijekova (naro~ito ibuprofena) i nuspojava. Nisu bile uo~ene posebnosti infekcija i/ili auto-
imunskih bolesti. Mehanizam tih ozbiljnih nuspojava mo`e se objasniti kao reakcija preosjetljivosti koja obuhva}a
mo`dane ovojnice i, djelomi~no, pu`nicu.
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